BRCA1 and ovarian carcinoma: In the PAOLA-1 phase 3 trial (NCT02477644), patients suffering from platinum-responsive ovarian cancer classified as HRD-positive based on the HRD score (≥42; Myriad myChoice® CDx) demonstrated better response to olaparib even when no BRCA1/2 mutations were present [86].